BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
Published on 02/26/2026 at 13:20 | businesswireindia.com- Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods
- Global BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, increases of 38% and 49% from the prior-year periods
- Diluted GAAP Earnings per American Depository Share (ADS) of $0.58 and $2.53 for the fourth quarter and full year; non-GAAP diluted Earnings per ADS of $1.95 and $8.09 for the fourth quarter and full year
- Full year 2026 total revenue guidance of $6.2 billion to $6.4 billion
(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025.
“These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in clinical development and manufacturing and one of the industry’s deepest and most differentiated pipelines,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA has firmly established itself as the global leader in the BTK inhibitor class, distinguished by broad regulatory approvals, expanding geographic reach, strong physician adoption, and unmatched long-term efficacy and safety data in CLL. At the same time, we are securing new indications and expanded reimbursement for TEVIMBRA across key markets worldwide. With our late-stage, foundational hematology assets nearing commercialization and a robust solid tumor portfolio delivering encouraging data, we are well positioned to extend our leadership and drive the next phase of sustainable global growth.”
(Amounts in thousands of U.S. dollars full year GAAP amounts audited, all other amounts unaudited)
|
|
|
Fourth Quarter |
|
|
|
Full Year |
|
|
||||||||||||
|
|
|
2025 |
|
2024 |
|
% Change |
|
2025 |
|
2024 |
|
% Change |
||||||||
|
Net product revenues |
|
$ |
1,476,442 |
|
$ |
1,118,035 |
|
|
32 |
% |
|
$ |
5,282,061 |
|
$ |
3,779,546 |
|
|
40 |
% |
|
Other revenue |
|
$ |
21,728 |
|
$ |
9,789 |
|
|
122 |
% |
|
$ |
60,972 |
|
$ |
30,695 |
|
|
99 |
% |
|
Total revenue |
|
$ |
1,498,170 |
|
$ |
1,127,824 |
|
|
33 |
% |
|
$ |
5,343,033 |
|
$ |
3,810,241 |
|
|
40 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
GAAP income (loss) from operations |
|
$ |
185,035 |
|
$ |
(79,425 |
) |
|
333 |
% |
|
$ |
447,136 |
|
$ |
(568,199 |
) |
|
179 |
% |
|
Adjusted income from operations* |
|
$ |
344,476 |
|
$ |
78,603 |
|
|
338 |
% |
|
$ |
1,099,962 |
|
$ |
45,356 |
|
|
2325 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
GAAP net income (loss) |
|
$ |
66,502 |
|
$ |
(151,881 |
) |
|
144 |
% |
|
$ |
286,933 |
|
$ |
(644,786 |
) |
|
145 |
% |
|
Adjusted net income (loss)* |
|
$ |
224,979 |
|
$ |
16,101 |
|
|
1297 |
% |
|
$ |
917,601 |
|
$ |
(54,919 |
) |
|
1771 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
GAAP basic earnings (loss) per ADS |
|
$ |
0.60 |
|
$ |
(1.43 |
) |
|
142 |
% |
|
$ |
2.63 |
|
$ |
(6.12 |
) |
|
143 |
% |
|
Adjusted basic earnings (loss) per ADS* |
|
$ |
2.03 |
|
$ |
0.15 |
|
|
1253 |
% |
|
$ |
8.41 |
|
$ |
(0.52 |
) |
|
1717 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
GAAP diluted earnings (loss) per ADS |
|
$ |
0.58 |
|
$ |
(1.43 |
) |
|
141 |
% |
|
$ |
2.53 |
|
$ |
(6.12 |
) |
|
141 |
% |
|
Adjusted diluted earnings (loss) per ADS* |
|
$ |
1.95 |
|
$ |
0.15 |
|
|
1200 |
% |
|
$ |
8.09 |
|
$ |
(0.52 |
) |
|
1656 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Free Cash Flow* |
|
$ |
379,825 |
|
$ |
(17,320 |
) |
|
2293 |
% |
|
$ |
941,741 |
|
$ |
(633,294 |
) |
|
249 |
% |
|
* For an explanation of our use of non-GAAP financial measures refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release. |
Fourth Quarter and Full Year 2025 Financial Results
Product Revenue, which represents 99% of total revenue, totaled $1.5 billion and $5.3 billion for the fourth quarter and full year of 2025, representing growth of 32% and 40%, compared to the prior-year periods.
- BRUKINSA: Global sales totaled $1.1 billion and $3.9 billion the fourth quarter and full year of 2025, representing growth of 38% and 49%, compared to the prior-year periods; U.S. sales of BRUKINSA totaled $845 million and $2.8 billion in the fourth quarter and full year of 2025, representing growth of 37% and 45%, compared to the prior-year periods.
- TEVIMBRA (tislelizumab): Global sales totaled $182 million and $737 million, in the fourth quarter and full year of 2025, representing growth of 18% and 19%, compared to the prior-year periods.
- Amgen in-licensed products: Global sales totaled $112 million and $486 million for the fourth quarter and full year of 2025, representing growth of 11% and 33%, compared to prior-year periods.
Gross Margin as a percentage of global product sales for the fourth quarter and full year of 2025 was 90.4% and 87.3%, compared to 85.6% and 84.3%, in the prior-year periods on a GAAP basis. On an adjusted basis, which does not include depreciation and amortization, gross margin as a percentage of global product sales increased to 90.7% and 87.8% for the fourth quarter and full year of 2025, compared to 87.4% and 85.5%, in the prior-year periods.
Operating Expenses
The following table summarizes operating expenses for the fourth quarter of 2025 and 2024:
|
|
|
GAAP |
|
|
|
Non-GAAP |
|
|
||||||||||
|
(in thousands, except percentages) |
|
Q4 2025 |
|
Q4 2024 |
|
% Change |
|
Q4 2025 |
|
Q4 2024 |
|
% Change |
||||||
|
Research and development |
|
$ |
615,423 |
|
$ |
542,012 |
|
14 |
% |
|
$ |
544,823 |
|
$ |
474,874 |
|
15 |
% |
|
Selling, general and administrative |
|
$ |
555,290 |
|
$ |
504,677 |
|
10 |
% |
|
$ |
471,468 |
|
$ |
433,059 |
|
9 |
% |
|
Total operating expenses |
|
$ |
1,170,713 |
|
$ |
1,046,689 |
|
12 |
% |
|
$ |
1,016,291 |
|
$ |
907,933 |
|
12 |
% |
The following table summarizes operating expenses for the full year 2025 and 2024:
|
|
|
GAAP |
|
|
|
en | boerse | 68614579 |
| |||||
